#Italy #Milan #Newronika #αDBS #WebBioBank

Newronika's Innovative Leap in Deep Brain Stimulation Therapy

Newronika S.p.A., an innovative medical technology company based in Milan, has recently achieved a significant milestone in the realm of neurological therapy by securing CE Mark certification for its flagship product, αDBS®. This adaptive deep brain stimulation (DBS) system is set to redefine how treatments for neurological disorders, particularly Parkinson's disease, are delivered and monitored across Europe.

A Revolutionary Approach to DBS

The αDBS® system stands out in a field traditionally dominated by fixed-stimulation DBS systems. Unlike conventional methods that apply the same level of stimulation throughout the day regardless of the changing needs of the patient, αDBS® employs a patented Adaptive Therapy Stim Engine. This technology continuously monitors the brain's local field potentials (LFPs) in real-time. By reading the brain's signals, this system can automatically adjust the stimulation levels to maintain each patient's optimal therapeutic output. This not only enhances treatment effectiveness but also minimizes potential side effects, leading to fewer clinical visits – a significant advantage for both patients and healthcare providers.

Integrated Data Systems

Central to the success of the αDBS® system is its seamless integration with Newronika’s WebBioBank™ neural data platform. This innovation allows for the real-time transmission of data collected from the implanted device to a cloud-based repository. The WebBioBank™ system is designed to analyze and store neural signals alongside clinical data, creating a comprehensive, longitudinal dataset that advances the overall understanding of deep brain stimulation mechanisms.

This platform not only enhances patient care but serves as a powerful research tool, significantly broadening the scope for further discoveries in neuromodulation therapies. Developed with support from Italy's Ministry of Education, the WebBioBank™ architecture prioritizes patient privacy by ensuring data de-identification across all participating clinical centers.

Impact on Patient Care

This regulatory achievement symbolizes a leap towards personalization in medical treatment. Recognizing the unique nature of each patient's condition, Newronika’s adaptive system is designed to cater to individual neurological profiles, offering treatments that are responsive rather than static. Lorenzo Rossi, PhD, Co-Founder and CEO of Newronika, emphasized that this certification not only validates their vision of a connected, data-driven therapeutic approach but also marks the beginning of a new era in managing Parkinson's disease and other neurological disorders.

Future Aspirations and FDA Approval

to further expand its reach and impact, Newronika is concurrently working towards securing FDA approval for αDBS® in the United States. The company has initiated the ADVENT pivotal trial, which spans both the U.S. and the EU, designed to support the approval processes for both conventional and adaptive DBS systems for Parkinson’s treatment. While the device remains investigational in the U.S., the success of the trial could pave the way for widespread use and acceptance of this next-generation therapy.

Conclusion

Newronika S.p.A. is at the forefront of deep brain stimulation innovation, leveraging decades of research to deliver cutting-edge solutions for neurological conditions. With the successful CE Mark certification of αDBS®, the company is not just advancing its products but also pushing the boundaries of what is possible in personalized medicine. As healthcare continues to evolve with technology, Newronika represents a leading example of how data-driven, adaptive therapies can transform lives.

For more details about Newronika’s innovations and WebBioBank™, please visit Newronika and WebBioBank.